GlassScriptPhysician profile
Cassandra Lacher
NPI 1467746651
$1,334.20
in general payments reported to CMS, 2019-2025
26 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $23.99 · 2021: $40.70 · 2022: $17.93 · 2023: $285 · 2024: $554 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,079.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $173.33 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $134.52 | 2021-2025 | Keytruda, Lynparza |
| Celgene Corporation | $114.91 | 2023-2025 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $107.45 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $93.63 | 2023-2024 | Enhertu, Imfinzi, Lynparza |
| Tersera Therapeutics LLC | $81.14 | 2024 | Zoladex, Xermelo |
| Lilly USA, LLC | $67.06 | 2024 | Verzenio, Retevmo, Jaypirca |
| Eisai INC. | $66.83 | 2023 | |
| Incyte Corporation | $55.27 | 2023-2024 | Pemazyre, Monjuvi |
| Jazz Pharmaceuticals INC. | $54.80 | 2024-2025 | |
| Janssen Biotech, INC. | $53.74 | 2024-2025 | Imbruvica, Talvey, Darzalex |
| Tempus Ai, INC | $43.66 | 2024 | |
| Boston Scientific Corporation | $38.24 | 2024-2025 | Spaceoar Vue System - 10ml |
| Abbvie INC. | $27.80 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.99 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $23.68 | 2024 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.03 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $21.21 | 2024 | Libtayo |
| Pfizer INC. | $20.89 | 2024 | |
| Rigel Pharmaceuticals, INC. | $19.76 | 2023 | Tavalisse, Rezlidhia |
| Myriad Genetic Laboratories, INC. | $17.93 | 2022 | |
| Genentech USA, INC. | $16.36 | 2023 | Lunsumio, Columvi, Polivy |
| Daiichi Sankyo INC. | $15.69 | 2023 | Enhertu |
| Glaxosmithkline, LLC. | $15.12 | 2025 | Jemperli, Zejula |
| Novocure INC. | $13.24 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Lacher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.